Abstract

Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate

Author(s): Wu George, Yeung Stanley, Chen Frank

Issue: Jan/Feb 2017 - Volume 21, Number 1

Page(s): 66-75

Download in electronic PDF format for $75
  • Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Page 1
  • Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Page 2
  • Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Page 3
  • Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Page 4
  • Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Page 5
  • Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Page 6
  • Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Page 7
  • Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Page 8
  • Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Page 9
  • Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate Page 10

Abstract

Neurokinin-1 receptor antagonist, 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone combination therapy is the standard of care for the prevention of chemotherapy-induced nausea and vomiting. Herein, we describe the physical and chemical stability of an injectable emulsion of the Neurokinin-1 receptor antagonist rolapitant 185 mg in 92.5 mL (free base, 166.5 mg in 92.5 mL) admixed with either 2.5 mL of dexamethasone sodium phosphate (10 mg) or 5 mL of dexamethasone sodium phosphate (20 mg). Admixtures were prepared and stored in two types of container closures (glass and Crystal Zenith plastic bottles) and four types of intravenous administration tubing sets (or intravenous tubing sets). The assessment of the physical and chemical stability was conducted on admixtures packaged in bottled samples stored at room temperature (20°C to 25°C under fluorescent light) and evaluated at 0, 1, and 6 hours. For admixtures in intravenous tubing sets, the assessment of physicochemical stability was performed after 0 and 7 hours of storage at 20°C to 25°C, and then after 20 hours (total 27 hours) under refrigeration (2°C to 8°C) and protected from light. Physical stability was assessed by visually examining the bottle contents under normal room light and measuring turbidity and particulate matter. Chemical stability was assessed by measuring the pH of the admixture and determining drug concentrations through high-performance liquid chromatographic analysis. Results showed that all samples were physically compatible throughout the duration of the study. The admixtures stayed within narrow and acceptable ranges in pH, turbidity, and particulate matter. Admixtures of rolapitant and dexamethasone were chemically stable when stored in glass and Crystal Zenith bottles for at least 6 hours at room temperature, as well as in the four selected intravenous tubing sets for 7 hours at 20°C to 25°C and then for 20 (total 27 hours) hours at 2°C to 8°C. No loss of potency of any admixed component occurred in the samples stored at the temperature ranges studied.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
Jan/Feb 2017
Pg. 66-75
Jan/Feb 2017
Pg. 76-82
Jan/Feb 2018
Pg. 86-94
Jan/Feb 2018
Pg. 76-85
May/Jun 2018
Pg. 237
Author(s): Allen Loyd V Jr
Mar/Apr 2018
Pg. 151
Author(s): Allen Loyd V Jr
Nov/Dec 2015
Pg. 508
Author(s): Allen Loyd V Jr
Sep/Oct 2004
Pg. 398-403
Sep/Oct 2005
Pg. 339-346
Author(s): Mishkan Emilyn S
Mar/Apr 2003
Pg. 155-159
Jul/Aug 2015
Pg. 344-347
Nov/Dec 2007
Pg. 520-524
Sep/Oct 2008
Pg. 460-462
Jul/Aug 2014
Pg. 278-286
Mar/Apr 2016
Pg. 167-174
Mar/Apr 2024
Pg. 100-109
Mar/Apr 2008
Pg. 156-160
Mar/Apr 2008
Pg. 170-173
Jan/Feb 2000
Pg. 26-27
Author(s): Jones Marty
Jan/Feb 2013
Pg. 66
Author(s): Allen Loyd V Jr